| STAT3 activation-induced fatty acid oxidation in CD8+ T effector cells is critical for obesity-promoted breast tumor growth C Zhang, C Yue, A Herrmann, J Song, C Egelston, T Wang, Z Zhang, W Li, ... Cell metabolism 31 (1), 148-161. e5, 2020 | 233 | 2020 |
| Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines Q Zhu, C Egelston, A Vivekanandhan, S Uematsu, S Akira, DM Klinman, ... Proceedings of the National Academy of Sciences 105 (42), 16260-16265, 2008 | 214 | 2008 |
| Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice Q Zhu, C Egelston, S Gagnon, Y Sui, IM Belyakov, DM Klinman, ... The Journal of clinical investigation 120 (2), 607-616, 2010 | 212 | 2010 |
| Human breast tumor-infiltrating CD8+ T cells retain polyfunctionality despite PD-1 expression CA Egelston, C Avalos, TY Tu, DL Simons, G Jimenez, JY Jung, ... Nature communications 9 (1), 4297, 2018 | 129 | 2018 |
| Resident memory CD8+ T cells within cancer islands mediate survival in breast cancer patients CA Egelston, C Avalos, TY Tu, A Rosario, R Wang, S Solomon, ... JCI insight 4 (19), 2019 | 93 | 2019 |
| Suppression of dendritic cell maturation and T cell proliferation by synovial fluid myeloid cells from mice with autoimmune arthritis C Egelston, J Kurkó, T Besenyei, B Tryniszewska, TA Rauch, TT Glant, ... Arthritis & Rheumatism 64 (10), 3179-3188, 2012 | 64 | 2012 |
| Identification of shared TCR sequences from T cells in human breast cancer using emulsion RT-PCR DJ Munson, CA Egelston, KE Chiotti, ZE Parra, TC Bruno, BL Moore, ... Proceedings of the National Academy of Sciences 113 (29), 8272-8277, 2016 | 62 | 2016 |
| A phase II clinical trial of pembrolizumab and enobosarm in patients with androgen receptor‐positive metastatic triple‐negative breast cancer Y Yuan, JS Lee, SE Yost, PH Frankel, C Ruel, CA Egelston, W Guo, ... The oncologist 26 (2), 99-e217, 2021 | 57 | 2021 |
| Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer Y Yuan, JS Lee, SE Yost, PH Frankel, C Ruel, CA Egelston, W Guo, ... European Journal of Cancer 154, 11-20, 2021 | 44 | 2021 |
| Development of proteoglycan-induced arthritis depends on T cell-supported autoantibody production, but does not involve significant influx of T cells into the joints A Angyal, C Egelston, T Kobezda, K Olasz, A László, TT Glant, K Mikecz Arthritis research & therapy 12, 1-16, 2010 | 38 | 2010 |
| MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection DV Rozanov, ND Rozanov, KE Chiotti, A Reddy, PA Wilmarth, LL David, ... Journal of proteomics 176, 13-23, 2018 | 35 | 2018 |
| A Pilot Feasibility Study of Yttrium‐90 Liver Radioembolization Followed by Durvalumab and Tremelimumab in Patients with Microsatellite Stable Colorectal Cancer Liver Metastases C Wang, J Park, C Ouyang, JA Longmate, M Tajon, J Chao, D Lim, ... The Oncologist 25 (5), 382-e776, 2020 | 29 | 2020 |
| Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor–positive breast cancer CA Egelston, W Guo, J Tan, C Avalos, DL Simons, MH Lim, YJ Huang, ... JCI insight 7 (3), 2022 | 23 | 2022 |
| Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive … C Egelston, W Guo, S Yost, JS Lee, D Rose, C Avalos, J Ye, P Frankel, ... Journal for Immunotherapy of Cancer 9 (3), 2021 | 19 | 2021 |
| Dissecting response to cancer immunotherapy by applying bayesian network analysis to flow cytometry data AS Rodin, G Gogoshin, S Hilliard, L Wang, C Egelston, RC Rockne, ... International Journal of Molecular Sciences 22 (5), 2316, 2021 | 15 | 2021 |
| Mature dendritic cells may promote high-avidity tuning of vaccine T cell responses A Kumbhari, CA Egelston, PP Lee, PS Kim Frontiers in Immunology 11, 584680, 2020 | 10 | 2020 |
| Genomic markers of CDK 4/6 inhibitor resistance in hormone receptor positive metastatic breast cancer JS Lee, SE Yost, SM Li, Y Cui, PH Frankel, YC Yuan, D Schmolze, ... Cancers 14 (13), 3159, 2022 | 9 | 2022 |
| CD8+ tissue resident memory T cells are associated with good prognosis in breast cancer patients C Egelston, G Srinivasan, C Avalos, Y Huang, A Rosario, R Wang, ... The Journal of Immunology 198 (1_Supplement), 196.11-196.11, 2017 | 9 | 2017 |
| Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer CA Egelston, W Guo, SE Yost, X Ge, JS Lee, PH Frankel, Y Cui, C Ruel, ... Cancer Immunology, Immunotherapy 72 (9), 3013-3027, 2023 | 8 | 2023 |
| Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade M Mei, L Chen, J Godfrey, J Song, C Egelston, S Puverel, LE Budde, ... Blood 142 (16), 1359-1370, 2023 | 5 | 2023 |
